Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients.

Cancers (Basel) · 2021 · PMC7958129 · PMID 33801285

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In the current study, PS 3 patients ( n = 35) exhibited a median 4.4-month OS, as compared with 1.1 months for PS 4 patients ( n = 6), yet this difference did not reach statistical significance, which is likely due to the limited sample size.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.